SELLAS Life Sciences Group
Market cap $3.90B 203.9M shares (10-Q, Nov 11, 2026) × $19.15 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- SLS009 AML Ph2 topline4Q 2026SLS009 AML Ph2 topline, 4Q 2026, material
- SLS009 Tambiciclib readoutDec 14, 2026SLS009 Tambiciclib readout, Dec 14, 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (9 active programs)
galinpepimut-S
GPSGPS+
- Undisclosed indication
tambiciclib
SLS009Capital (as filed)
- Cash
- $135M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$5.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $138M cash per the update of Oct 28, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-18 UPDATE: SELLAS Life Sciences (SLS) - The Coin Landed Heads 🔒 Paid
- 2026-11-05 UPDATE: SELLAS Life Sciences (SLS) - The Safety Net Gets Measured 🔒 Paid
- 2026-10-29 UPDATE: SELLAS Life Sciences (SLS) - Event #80 Is In 🔒 Paid
- 2026-08-12 UPDATE: SELLAS Life Sciences (SLS) - Three Months, Zero Events 🔒 Paid
- 2026-07-28 UPDATE: SELLAS Life Sciences (SLS) - The Stock Doubled, the Arbitration Died, and the Cash Grew 🔒 Paid
- 2026-05-12 UPDATE: SELLAS (SLS) - Two Events From the Bell 🔒 Paid
- 2026-03-22 UPDATE: SELLAS (SLS) - SEC Filings, Cash Runways, and a Peek at the Mechanism 🔒 Paid
- 2026-03-14 UPDATE: SELLAS (SLS) - Checking the Boxes on the SLS009 Pivot and Cash Runway 🔒 Paid
- 2025-12-29 SELLAS Life Sciences (SLS): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on SELLAS Life Sciences Group, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2025-12-29 Watch SELLAS Life Sciences (SLS): Scientific Due Diligence for Lead and Pipeline Products Binary event gamble on GPS Phase 3 REGAL readout with SLS009 as a scientifically stronger backup; watch list given open-label trial risk and near-100% peptide vaccine Phase 3 failure rate.
- 2026-03-14 Hold UPDATE: SELLAS (SLS) - Checking the Boxes on the SLS009 Pivot and Cash Runway SLS009 dosed first patient on schedule and financing risk eliminated; thesis intact while awaiting REGAL binary readout.
- 2026-03-22 Hold UPDATE: SELLAS (SLS) - SEC Filings, Cash Runways, and a Peek at the Mechanism Financial runway confirmed at ~$114M pro-forma cash, SLS009 mechanism strengthening, but REGAL binary readout remains the primary catalyst and the wait continues.
- 2026-05-12 Hold UPDATE: SELLAS (SLS) - Two Events From the Bell REGAL is two events from unblinding with financing risk fully retired; hold into the imminent binary readout.
- 2026-07-28 Watch UPDATE: SELLAS Life Sciences (SLS) - The Stock Doubled, the Arbitration Died, and the Cash Grew Stock doubled with no data while still two events from unblinding; risk/reward has materially worsened for new money, and existing holders should consider position sizing given the coin flip at a doubled price.
- 2026-08-12 Watch UPDATE: SELLAS Life Sciences (SLS) - Three Months, Zero Events REGAL still at 78/80 events after three months with no update; fortress balance sheet intact but readout timing is indefinite and the price has doubled since spring, making the risk/reward worse for new money.
- 2026-10-29 Watch UPDATE: SELLAS Life Sciences (SLS) - Event #80 Is In Event #80 reached triggering database lock with topline guided by year-end; scientific risk fully intact but timeline risk is now gone, and existing holders should size for a coin flip landing within weeks.
- 2026-11-05 Watch UPDATE: SELLAS Life Sciences (SLS) - The Safety Net Gets Measured Full SLS009 Phase 2 data shows 34% ORR across all comers vs. the previously cited 46% headline, confirming the safety net is real but smaller; REGAL binary still decides the stock.
- 2026-11-18 Speculative buy speculative UPDATE: SELLAS Life Sciences (SLS) - The Coin Landed Heads REGAL met its primary OS endpoint (HR 0.59, 24.0 vs 14.7 months) against a robust control arm that addresses the main open-label objection; upgrading to speculative buy pending secondary endpoints and FDA feedback.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“At the same time, we are making meaningful progress with SLS009 in our ongoing Phase 2 frontline AML study, where dosing continues and enrollment is tracking ahead of industry standards, with topline data expected in the fourth quarter of 2026.”
matched to GPS (Galinpepimut-S) · regulatory submission / matched to SLS009 (Phase 2 frontline AML) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (28)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseSELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaning→ BD updateSummary on the 8-K
- Nov 17, 2026ReleaseSELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering→ BD updateSummary on the 8-K
- Nov 17, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateThe Binary Event Gamble I've tracked since the original deep dive just landed on heads: REGAL hit its primary OS endpoint with GPS showing a hazard ratio of 0.59, p=0.035, and a median OS of 24.0 months versus 14.7 months for best available treatment — and SELLAS immediately launched a $150M underwritten public offering to fund the BLA sprint.
- Nov 17, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- Nov 12, 2026ReleaseSELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1
- Nov 12, 202610-QQuarterly report
- Nov 4, 2026ReleaseSELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026→ BD updateWith the REGAL binary imminent, SELLAS's Plan B just got a lot more real: SLS009 Phase 2 data headed to ASH shows 54–57% ORR in venetoclax-failed, high-risk AML subgroups where historical survival is ~2.5 months — and the safety profile is clean.
- Oct 28, 2026ReleaseSELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia→ BD updateThe 80th REGAL event has arrived — the database lock, unblinding, and topline Phase 3 GPS readout are now queued for this quarter. The coin is finally in the air, and the stock is down -14.7% on the news.BD extracted 1 program update from this document → SLS pipeline
- Sep 25, 2026ReleaseSELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
- Sep 2, 2026ReleaseSELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
- Aug 11, 2026ReleaseSELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → SLS pipeline
- Aug 11, 202610-QQuarterly report
- Jul 27, 20268-KCurrent report: results of operations, other events
- Jun 25, 20268-KCurrent report: officer / director change
- Jun 18, 20268-KCurrent report: shareholder vote
- Jun 2, 20268-KCurrent report: other events
- May 14, 2026ReleaseSELLAS Life Sciences to Participate in Upcoming Investor Conferences
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- May 11, 2026ReleaseSELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Apr 23, 2026DEFA14AProxy soliciting material
- Apr 23, 2026DEF 14AProxy statement
- Mar 20, 2026S-3ASRAutomatic shelf registration
- Mar 19, 20268-KCurrent report: results of operations · EX-99.1
- Mar 19, 202610-KAnnual report
- Mar 11, 20268-KCurrent report: other events
8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Oct 27, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 31, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 16, 2026S-8Employee plan registration
- Apr 24, 2026SCHEDULE 13G/A13G amendment
- Apr 23, 2026ARSAnnual report to shareholders
- Mar 27, 2026SCHEDULE 13G/A13G amendment